J. Fra
About
J. Fra is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology.
According to data from OpenAlex, J. Fra has authored 40 papers receiving a total of 907 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Pulmonary and Respiratory Medicine, 26 papers in Oncology and 7 papers in Molecular Biology. Recurrent topics in J. Fra's work include Sarcoma Diagnosis and Treatment (13 papers), Lung Cancer Treatments and Mutations (12 papers) and Lung Cancer Research Studies (10 papers). J. Fra is often cited by papers focused on Sarcoma Diagnosis and Treatment (13 papers), Lung Cancer Treatments and Mutations (12 papers) and Lung Cancer Research Studies (10 papers). J. Fra collaborates with scholars based in Spain, United States and Italy. J. Fra's co-authors include Antonio López–Pousa, J. Buesa, Joan Maurel, Antonio Casado, Javier Martínez‐Trufero, Javier Martín‐Broto, J. Bonneterre, Jozef Šufliarský, Steinar Aamdal and Peter Mohr and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and British Journal of Cancer.
In The Last Decade
J. Fra
38 papers receiving 881 citations
Peers
J. Fra
Maria Marples United Kingdom
Mona Fouad Egypt
G. R. Blumenschein United States
Ingo Alldinger Germany
Geraldine Goss Australia
Jeff White United Kingdom
Mustapha Tehfé Canada
Meredith K. Chuk United States
B. Nelson United States
Shefali Chopra United States
Citations per year, relative to J. Fra J. Fra (= 1×)
peers
Maria Marples
Countries citing papers authored by J. Fra
Since
Specialization
Citations
This map shows the geographic impact of J. Fra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Fra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Fra more than expected).
Fields of papers citing papers by J. Fra
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by J. Fra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Fra. The network helps show where J. Fra may publish in the future.
Co-authorship network of co-authors of J. Fra
This figure shows the co-authorship network connecting the top 25 collaborators of J. Fra. A scholar is included among the top collaborators of J. Fra based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Fra. J. Fra is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Fra, J., et al.. (2025). TERT Amplification a Risk Stratification Marker in Papillary Thyroid Carcinoma, Significantly Correlated with Tumor Recurrence and Survival. Endocrine Pathology. 36(1). 15–15.
2.
Armentia, Alicia, et al.. (2021). Inhaled corticosteroids may have a protective effect against coronavirus infection. Allergologia et Immunopathologia. 49(1). 113–117.
3.
Fra, J., et al.. (2020). Una respuesta ética en la atención a residencias de ancianos en la pandemia Covid-19. Cuadernos de bioética. 31(102). 223–229.
4.
Maurel, Joan, Antonio López–Pousa, Silvia Calabuig‐Fariñas, et al.. (2016). Phosphorylated-insulin growth factor I receptor (p-IGF1R) and metalloproteinase-3 (MMP3) expression in advanced gastrointestinal stromal tumors (GIST). A GEIS 19 study. PubMed. 6(1). 10–10.
5.
Rubió‐Casadevall, Jordi, Javier Martínez‐Trufero, Xabier García‐Albéniz, et al.. (2015). Role of Surgery in Patients with Recurrent, Metastatic, or Unresectable Locally Advanced Gastrointestinal Stromal Tumors Sensitive to Imatinib: A Retrospective Analysis of the Spanish Group for Research on Sarcoma (GEIS). Annals of Surgical Oncology. 22(9). 2948–2957.
6.
Sierra, Marta, et al.. (2012). Long-term biomonitoring of breast cancer patients under adjuvant chemotherapy: the comet assay as a possible predictive factor. Mutagenesis. 28(1). 39–48.
7.
Muro, Xavier García del, Antonio López–Pousa, Joan Maurel, et al.. (2011). Randomized Phase II Study Comparing Gemcitabine Plus Dacarbazine Versus Dacarbazine Alone in Patients With Previously Treated Soft Tissue Sarcoma: A Spanish Group for Research on Sarcomas Study. Journal of Clinical Oncology. 29(18). 2528–2533.
8.
Esteban, Emilio, Norberto Corral, Paula Jiménez Fonseca, et al.. (2010). Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias. Clinical & Translational Oncology. 12(8). 562–567.
9.
Esteban, Emilio, N. Villanueva, J. Fra, et al.. (2010). Activity of topotecan given intravenously for 5 days every three weeks in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes: a phase II study. Investigational New Drugs. 29(6). 1459–1464.
10.
Esteban, Emilio, N. Villanueva, Yolanda Fernández, et al.. (2007). Pulmonary toxicity in patients treated with gemcitabine plus vinorelbine or docetaxel for advanced non-small cell lung cancer: outcome data on a randomized phase II study. Investigational New Drugs. 26(1). 67–74.
11.
Esteban, Emilio, N. Villanueva, Norberto Corral, et al.. (2006). Cisplatin plus gemcitabine with or without vinorelbine as induction chemotherapy prior to radical locoregional treatment for patients with stage III non-small-cell lung cancer (NSCLC): Results of a prospective randomized study. Lung Cancer. 55(2). 173–180.
12.
Esteban, Emilio, J. Fra, Yolanda Fernández, et al.. (2005). Gemcitabine and vinorelbine (GV) versus cisplatin, gemcitabine and vinorelbine (CGV) as first-line treatment in advanced non small cell lung cancer: Results of a prospective randomized phase II study. Investigational New Drugs. 24(3). 241–248.
13.
Buesa, J., et al.. (2004). Phase I clinical trial of fixed–dose rate infusional gemcitabine and dacarbazine in the treatment of advanced soft tissue sarcoma, with assessment of gemcitabine triphosphate accumulation. Cancer. 101(10). 2261–2269.
14.
Maurel, Joan, J. Fra, Antonio López–Pousa, et al.. (2004). Sequential dose‐dense doxorubicin and ifosfamide for advanced soft tissue sarcomas. Cancer. 100(7). 1498–1506.
15.
Esteban, Emilio, Yolanda Fernández, Norberto Corral, et al.. (2003). Prospective randomised phase II study of docetaxel versus paclitaxel administered weekly in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. Annals of Oncology. 14(11). 1640–1647.
16.
Viéitez, José María, et al.. (2003). Irinotecan in the Treatment of Advanced Colorectal Cancer in Patients Pretreated With Fluorouracil-Based Chemotherapy. American Journal of Clinical Oncology. 26(2). 107–111.
17.
Esteban, Emilio, Isabel Palacio, Yolanda Fernández, et al.. (2003). Combination of Docetaxel, Epirubicin and Vinorelbine Administered Every 2 Weeks as First-line Therapy in Patients with Metastatic Breast Cancer: A Dose-finding Study. Breast Cancer Research and Treatment. 80(3). 257–265.
18.
Esteban, Emilio, J. Fra, Norberto Corral, et al.. (2002). Phase I/II Study of Gemcitabine plus Vinorelbine in Non-Small Cell Lung Cancer. Investigational New Drugs. 20(1). 73–82.
19.
Esteban, Emilio, et al.. (2000). A phase II trial of cyclophosphamide, epirubicin and vinorelbine in the treatment of advanced breast cancer. Breast Cancer Research and Treatment. 62(2). 127–133.
20.
Buesa, J., J. Fra, A. Antón, et al.. (1998). Activity of doxorubicin after high-dose ifosfamide in adult patients with advanced soft tissue sarcoma: A study of the Spanish Group for Research on Sarcomas (GEIS). Annals of Oncology. 9(7). 783–785.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Maria Marples Breakdown of academic impact, for papers by Mona Fouad Breakdown of academic impact, for papers by G. R. Blumenschein Breakdown of academic impact, for papers by Ingo Alldinger Breakdown of academic impact, for papers by Geraldine Goss Breakdown of academic impact, for papers by Jeff White Breakdown of academic impact, for papers by Mustapha Tehfé Breakdown of academic impact, for papers by Meredith K. Chuk Breakdown of academic impact, for papers by B. Nelson Breakdown of academic impact, for papers by Shefali Chopra